Stockreport

Can CorMedix's Melinta Acquisition Aid Growth Beyond DefenCath? [Yahoo! Finance]

CorMedix Inc.  (CRMD) 
NASDAQ:AMEX Investor Relations: cormedix.com
PDF acquiring Melinta Therapeutics for $300 million in August 2025. The deal added seven approved products to CRMD's portfolio, while diversifying its commercial portfolio a [Read more]